Cetuximab biosimilar - Sichuan Kelun PharmaceuticalAlternative Names: Recombinant anti-EGFr antibody
Latest Information Update: 02 Feb 2017
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer
Most Recent Events
- 01 Dec 2016 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT03017807)